Last updated: October 29, 2026
NovoLog Mix 70/30 is a mature insulin analog product containing 70% insulin aspart protamine suspension and 30% insulin aspart. Novo Nordisk markets the product in the United States for adults with diabetes who require mealtime and basal insulin coverage. Its commercial trajectory is shaped by patent expiry, lower-cost insulin programs, payer pressure, and the shift toward flexible basal-bolus regimens and GLP-1 therapies.
Novo Nordisk does not disclose revenue for NovoLog Mix 70/30 separately. Financial analysis therefore relies on the company’s broader insulin portfolio, product availability, pricing actions, prescription trends, and the competitive position of premixed insulin.
What is NovoLog Mix 70/30 and how does it work?
NovoLog Mix 70/30 is a premixed biologic insulin product with two components:
| Product attribute |
NovoLog Mix 70/30 |
| Active ingredients |
Insulin aspart protamine suspension and insulin aspart |
| Ratio |
70% intermediate-acting component and 30% rapid-acting component |
| Manufacturer |
Novo Nordisk |
| U.S. regulatory status |
FDA-approved biologic |
| Primary use |
Type 1 and type 2 diabetes requiring insulin |
| U.S. dosage forms |
FlexPen, FlexTouch, and vial presentations, subject to market availability |
| Administration |
Subcutaneous injection |
| Typical use |
Before meals, often twice daily |
| Comparable product |
Humalog Mix75/25 |
| Broader therapeutic class |
Premixed insulin analogs |
The rapid-acting insulin aspart component addresses postprandial glucose, while the protamine-bound component provides longer glucose-lowering activity. The fixed ratio simplifies treatment compared with separate basal and mealtime injections, but it restricts the ability to independently adjust basal and prandial insulin.
The FDA label states that NovoLog Mix 70/30 should be administered shortly before meals and that dose timing, meal composition, activity, and glucose monitoring affect outcomes.[1]
When did NovoLog Mix 70/30 lose market exclusivity?
NovoLog Mix 70/30 is a mature product with no meaningful remaining U.S. market exclusivity. The underlying insulin aspart intellectual-property estate was filed and prosecuted during the 1990s and early 2000s. The principal patent term for the original insulin aspart technology expired years ago, subject to patent-term adjustment and specific patent claims.
The commercial consequence is that Novo Nordisk competes primarily through manufacturing scale, physician familiarity, contracting, supply reliability, device access, and payer arrangements rather than patent exclusivity.
| Milestone |
Approximate timing |
| FDA approval of NovoLog insulin aspart |
2000 |
| FDA approval of NovoLog Mix 70/30 |
2001 |
| Core composition and insulin-aspart patent protection |
Expired during the 2010s |
| U.S. biosimilar pathway for insulin |
Available following biologic transition under the Biologics Price Competition and Innovation Act |
| Current branded exclusivity |
None of commercial significance |
| Current market position |
Mature, patent-expired insulin analog |
The product’s age does not eliminate barriers to competition. Insulin manufacturing requires complex fermentation, purification, formulation, analytical characterization, sterile filling, device integration, and regulatory validation. These operational requirements make insulin more difficult to reproduce than a conventional small-molecule generic.
What is the Orange Book status of NovoLog Mix 70/30?
NovoLog Mix 70/30 is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, under insulin aspart-containing product entries.[2] The product is regulated as a biologic, and the Orange Book does not provide a current period of market exclusivity comparable to the original approval exclusivity.
The principal commercial issue is not an active Orange Book patent barrier. It is the limited number of approved competitors and the complexity of developing a substitutable insulin product.
FDA regulatory pathways include:
- A 351(a) biologics license application for a novel biologic.
- A 351(k) abbreviated pathway for a biosimilar or interchangeable biosimilar.
- An abbreviated pathway for certain products that were historically regulated under the Federal Food, Drug, and Cosmetic Act and transitioned to the Public Health Service Act.
The FDA’s insulin transition increased the importance of biosimilar and interchangeable-biosimilar competition. The transition did not automatically create a substitutable biosimilar for NovoLog Mix 70/30.
Are there Paragraph IV challenges to NovoLog Mix 70/30?
There is no commercially material current Paragraph IV litigation landscape for NovoLog Mix 70/30 comparable to a recently launched small-molecule drug.
Paragraph IV certifications apply to listed patents in abbreviated new drug applications. Insulin products are biologics, and biosimilar applicants use the patent-information exchange and litigation framework under the Biologics Price Competition and Innovation Act rather than the conventional ANDA Paragraph IV process.
The practical conclusion is:
- Core patent protection has expired.
- No active patent dispute is central to current NovoLog Mix 70/30 competition.
- Competitive entry depends more on biosimilar development, interchangeability, manufacturing capacity, and payer contracts.
- Device and presentation patents may affect specific pen systems, but they do not recreate product-level exclusivity for insulin aspart.
What formulations and manufacturing rights protect NovoLog Mix 70/30?
The product’s remaining defensibility is concentrated in manufacturing and product execution rather than broad composition patents.
Relevant barriers include:
Formulation know-how
Premixed insulin products require control of particle size, suspension stability, concentration, aggregation, preservative systems, pH, and compatibility with injection devices. The 70/30 ratio must remain consistent throughout storage and administration.
Manufacturing process controls
Commercial-scale insulin production requires:
- Recombinant protein expression.
- Protein recovery and purification.
- Controlled conversion and crystallization.
- Protamine complex formation.
- Sterile formulation and filling.
- Stability testing across the labeled storage period.
These capabilities create a higher entry threshold than the absence of patents would suggest.
Device and presentation rights
Novo Nordisk has substantial experience with FlexPen and FlexTouch delivery systems. Device patents may protect specific injector architectures, dose mechanisms, manufacturing methods, or human-factors implementations. Competitors can avoid those claims through alternative devices, vials, or contract-manufactured presentations.
Regulatory comparability
A biosimilar developer must demonstrate high similarity to the reference insulin, with no clinically meaningful differences in safety, purity, or potency. Analytical similarity, immunogenicity assessment, pharmacokinetics, pharmacodynamics, and device performance determine development cost and timing.
How does NovoLog Mix 70/30 compare with Humalog Mix75/25 and human premixed insulin?
NovoLog Mix 70/30 competes across three product groups: premixed insulin analogs, human premixed insulin, and flexible basal-bolus therapy.
| Product |
Manufacturer |
Insulin type |
Commercial positioning |
| NovoLog Mix 70/30 |
Novo Nordisk |
Insulin aspart premix |
Brand analog with pen and vial options |
| Humalog Mix75/25 |
Eli Lilly |
Insulin lispro premix |
Primary branded analog competitor |
| Novolin 70/30 |
Novo Nordisk |
Human regular/NPH premix |
Lower-cost alternative |
| ReliOn insulin products |
Walmart and suppliers |
Human insulin and selected analog products |
Discount-channel access |
| Separate basal plus mealtime insulin |
Multiple manufacturers |
Flexible regimen |
Greater dosing flexibility, higher treatment complexity |
NovoLog Mix 70/30 has an efficacy and convenience profile suited to patients who prefer a simplified regimen. Humalog Mix75/25 is the closest branded analog competitor, while Novolin 70/30 and lower-cost insulin channels place the greatest pressure on price.
Premixed analogs are less flexible than separate basal and bolus insulin. A patient whose basal and mealtime requirements diverge may obtain better control from a basal-bolus regimen or an automated insulin delivery system.
What is the current market dynamic for premixed insulin?
The premixed insulin market is stable but structurally pressured.
Price compression
Insulin list prices and net prices have declined under pressure from public programs, commercial payers, employer groups, pharmacy benefit managers, and patient-affordability initiatives. Novo Nordisk announced major U.S. list-price reductions for several insulin products, including NovoLog, beginning in 2024.[3]
The price reduction supports patient access but reduces revenue per unit. For NovoLog Mix 70/30, the commercial effect depends on the portion of prescriptions subject to the lower list price, negotiated rebates, Medicare coverage, Medicaid reimbursement, and pharmacy-channel mix.
Channel fragmentation
Sales occur through retail pharmacies, mail order, Medicare Part D, Medicaid, commercial insurance, employer plans, and discount programs. The same product can produce materially different net revenue across channels.
Treatment substitution
Premixed insulin faces substitution from:
- Basal insulin plus rapid-acting mealtime insulin.
- Fixed-ratio basal insulin/GLP-1 products.
- GLP-1 receptor agonists.
- Dual GIP/GLP-1 therapies.
- Continuous glucose monitoring and automated insulin delivery systems.
- Lower-cost human insulin.
For insulin-dependent patients, these alternatives do not eliminate insulin demand. They can reduce use of premixed products in selected type 2 diabetes populations.
Supply reliability
Insulin shortages or manufacturing disruptions can alter market share quickly. Because the number of global insulin manufacturers is limited, hospitals, pharmacies, and payers place a high value on stable supply.
What is the financial trajectory of NovoLog Mix 70/30?
Novo Nordisk does not report NovoLog Mix 70/30 revenue as a separate line item. The product is included within broader insulin and diabetes-care results.
Novo Nordisk’s insulin sales have remained large but have grown more slowly than its obesity portfolio:
| Novo Nordisk financial indicator |
Direction |
| Insulin portfolio revenue |
Large, mature, and exposed to price pressure |
| Unit demand |
Supported by global diabetes prevalence |
| Net price |
Under sustained downward pressure |
| Product mix |
Moving toward newer and higher-value therapies |
| NovoLog Mix 70/30 contribution |
Not separately disclosed |
| Margin outlook |
Sensitive to U.S. rebates, discounts, manufacturing cost, and mix |
| Growth driver |
Volume and international demand rather than exclusivity |
Novo Nordisk reported total sales of approximately DKK 232 billion in 2023 and approximately DKK 290 billion in 2024, driven primarily by GLP-1-based diabetes and obesity products rather than mature insulin brands.[4][5] The company’s insulin franchise remained commercially important, but its share of total sales declined as Ozempic, Rybelsus, and Wegovy expanded.
For NovoLog Mix 70/30, the likely financial trajectory is:
- Stable or declining U.S. net revenue per unit.
- Continued demand from insulin-requiring patients.
- Lower growth than Novo Nordisk’s GLP-1 portfolio.
- Greater dependence on payer contracts and affordability programs.
- Increasing importance of international markets and lower-cost manufacturing.
- Potential volume support from diabetes prevalence and insulin access programs.
The product remains strategically useful because it generates recurring demand, uses established manufacturing infrastructure, and supports Novo Nordisk’s broader insulin portfolio. It is unlikely to be a major incremental growth driver.
How did Novo Nordisk’s pricing strategy affect NovoLog Mix 70/30?
Novo Nordisk announced a 75% reduction in the U.S. list price of NovoLog and related insulin products, effective in 2024, and expanded a $35 monthly out-of-pocket cap for many patients.[3] The company also markets lower-priced insulin options, including authorized unbranded versions in selected channels.
The financial effect is mixed:
- Patients paying list price may receive substantial savings.
- Insured patients may see limited direct benefit if rebates already reduced their out-of-pocket cost.
- Novo Nordisk may experience lower gross-to-net revenue per prescription.
- Lower prices can reduce substitution to human insulin or competing brands.
- Better affordability can support adherence and prescription retention.
- Payer negotiations remain central to realized net sales.
The pricing strategy reduces the ability of competitors to win solely through discounting, but it also compresses the value of a mature branded analog product.
What generic, biosimilar, and follow-on entry risks exist?
The risk of conventional generic entry is limited because insulin is a biologic. The more relevant threats are biosimilar, interchangeable-biosimilar, follow-on, and authorized-unbranded competition.
| Entry type |
Risk to NovoLog Mix 70/30 |
| Conventional ANDA generic |
Low relevance |
| Biosimilar insulin aspart |
Moderate long-term risk |
| Interchangeable biosimilar |
Higher substitution risk if approved |
| Authorized unbranded insulin |
Existing and material |
| Human insulin substitution |
High in price-sensitive segments |
| Competing premix analog |
Established risk from Humalog Mix75/25 |
| Device-only competition |
Limited unless linked to lower net cost |
An interchangeable biosimilar could create pharmacy-level substitution in jurisdictions where state law and payer policy permit it. The scale of the threat would depend on whether the entrant matches the reference product’s pen systems, vial availability, supply reliability, and payer formulary status.
What patent litigation and settlement agreements affect the product?
No active patent litigation or settlement agreement appears to define the current U.S. market for NovoLog Mix 70/30. The key legal transition occurred when the core insulin aspart patents reached the end of their enforceable terms.
Future disputes are more likely to involve:
- Biosimilar patent procedures.
- Device patents.
- Manufacturing processes.
- Trade secrets.
- Interchangeability and substitution.
- Contracting and rebate practices.
- Product labeling or supply obligations.
The lack of active product-level patent litigation means that a new entrant would not normally need to wait for a Hatch-Waxman settlement date. Regulatory readiness, manufacturing validation, and payer access would be the primary launch constraints.
What is the geographic market outlook for NovoLog Mix 70/30?
The United States is the most important market for pricing and litigation analysis, but international demand remains significant.
Outside the United States, NovoLog Mix 70/30 is commonly associated with NovoMix 30 branding. Market access depends on national reimbursement systems, tender procurement, local substitution rules, insulin affordability, and supply capacity.
Emerging markets offer volume growth because diabetes prevalence is increasing and insulin access remains incomplete. They also carry lower prices, currency risk, government tender pressure, and a greater likelihood of substitution by human insulin.
In high-income markets, the product is more exposed to biosimilar competition, formulary exclusion, and replacement by newer diabetes medicines. In lower-income markets, price and supply reliability are more important than delivery-system differentiation.
How strong is the patent estate for NovoLog Mix 70/30?
The current patent estate is weak as a source of exclusivity but strong as a historical manufacturing platform.
| Patent-estate dimension |
Assessment |
| Core composition patents |
Expired |
| Market exclusivity |
None of practical commercial significance |
| Formulation know-how |
Important but difficult to enforce independently |
| Delivery-device patents |
Potentially relevant to specific pens |
| Manufacturing trade secrets |
Significant operational barrier |
| Biosimilar litigation risk |
Possible, but not currently market-defining |
| Overall commercial moat |
Manufacturing, scale, contracting, and brand familiarity |
NovoLog Mix 70/30 is therefore a scale-and-access product rather than a patent-protected growth asset.
What are the most likely generic launch scenarios?
Three scenarios are commercially plausible.
Scenario one: Gradual erosion
A biosimilar or follow-on insulin aspart enters with limited formulary access. Novo Nordisk retains share through physician familiarity, supply reliability, pen availability, and contracting. Net price declines, while unit volume remains relatively stable.
Scenario two: Interchangeable substitution
An interchangeable biosimilar gains broad pharmacy and payer adoption. The product experiences faster share loss, particularly in price-sensitive type 2 diabetes populations. Novo Nordisk protects the franchise through rebates, lower-priced versions, and device differentiation.
Scenario three: Premix market contraction
Patients move from premixed insulin to basal-bolus regimens, GLP-1 therapies, or dual incretin therapies. NovoLog Mix 70/30 loses both price and volume, with demand concentrated among patients who value simplified dosing or cannot access newer therapies.
The most probable base case is gradual price erosion with selective volume resilience, rather than an abrupt loss of the franchise.
Key Takeaways
- NovoLog Mix 70/30 is a mature insulin analog with no meaningful remaining product exclusivity.
- Novo Nordisk does not disclose product-specific revenue, so financial performance must be inferred from the broader insulin portfolio.
- The product’s main competitors are Humalog Mix75/25, Novolin 70/30, lower-cost insulin programs, and flexible basal-bolus regimens.
- U.S. list-price reductions reduce revenue per unit but may support access and prescription retention.
- The principal barriers to entry are biologic manufacturing, formulation control, device integration, regulatory comparability, and payer contracting.
- Biosimilar and interchangeable-biosimilar entry represent the main long-term competitive threat.
- NovoLog Mix 70/30 is more likely to remain a recurring cash-generating product than a material growth driver for Novo Nordisk.
FAQs
Is NovoLog Mix 70/30 still commercially important?
Yes. It remains relevant for insulin-requiring patients who use a simplified premixed regimen, although its growth rate is below that of Novo Nordisk’s GLP-1 products.
Is NovoLog Mix 70/30 interchangeable with Novolin 70/30?
No. NovoLog Mix 70/30 contains insulin aspart, while Novolin 70/30 contains human regular insulin and NPH insulin. They have different pharmacokinetic profiles and should not be substituted without clinical supervision.
Does NovoLog Mix 70/30 have biosimilar competition?
There is no widely established interchangeable biosimilar equivalent that has displaced the product in the U.S. market. The regulatory pathway remains available for future insulin aspart competitors.
Will GLP-1 drugs eliminate demand for NovoLog Mix 70/30?
No. GLP-1 and dual incretin therapies may reduce insulin use for some patients with type 2 diabetes, but patients with type 1 diabetes and many insulin-dependent patients will continue to require insulin.
Is NovoLog Mix 70/30 a high-value patent asset for Novo Nordisk?
No. Its commercial value comes from recurring demand, manufacturing scale, brand recognition, supply capacity, and payer relationships rather than active composition patent protection.
References
- U.S. Food and Drug Administration. (2024). NovoLog Mix 70/30 insulin aspart injection prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Novo Nordisk A/S. (2024). Novo Nordisk announces lower U.S. insulin list prices and expanded affordability programs.
- Novo Nordisk A/S. (2024). Annual report 2023.
- Novo Nordisk A/S. (2025). Annual report 2024.
- U.S. Food and Drug Administration. (2020). Insulin products regulated under the Public Health Service Act.
